期刊
LANCET
卷 376, 期 9740, 页码 517-523出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)60935-X
关键词
-
资金
- Sanofi-Aventis
- Servier
- AstraZeneca
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- GlaxoSmithKline
- Menarini
- Medtronic
- Nycomed
- Pierre Fabre
- Medicines Company
- Astellas
- Bayer
- Daiichi-Sankyo
- MSD
- Otsuka
- Eisai
- Ethicon
- Heartscape
- Eli Lilly Canada
- Torrent Pharmaceuticals
- Teratechnologies
- Abbott Laboratories
- Merck
- Pfizer
- Solvay Pharma
- Novartis
- Guerbet Medical
- Boston Scientific
- Cordis
- Sago
- Centocor
- Fondation de France
- INSERM
- Federation Francaise de Cardiologie
- Societe Francaise de Cardiologie
- ITC Edison
- Schering-Plough
- Portola
- Merck Sharpe St Dohme
- Accumetrics
- Scripps Translational Science institute [NIH UL1 RR025774]
Background Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival. Methods This double-blind, placebo-controlled trial was undertaken in 974 hospitals in 42 countries. 18 695 patients with previously manifest or increased risk of vascular disease were randomly assigned to receive either rimonabant 20 mg (n=9381) or matching placebo (n=9314). Randomisation was stratified by centre, implemented with an independent interactive voice response system, and all study personnel and participants were masked to group assignment. The primary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke, as determined via central adjudication. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00263042. Findings At a mean follow-up of 13.8, months (95% CI 13.6-14.0), the trial was prematurely discontinued because of concerns by health regulatory authorities in three countries about suicide in individuals receiving rimonabant. All randomised participants were analysed. At the close of the trial (Nov 6, 2008), the composite primary endpoint of cardiovascular death, myocardial infarction, or stroke occurred in 364 (3.9%) patients assigned to rimonabant and 375 (4.0%) assigned to placebo (hazard ratio 0.97, 95% CI 0.84-1.12, p=0.68). With rimonabant, gastrointestinal (3038 [33%] vs 2084 [22%]), neuropsychiatric (3028 [32%] vs 1989 [21%]), and serious psychiatric side-effects (232 [2.5%] vs 120 [1.3%]) were significantly increased compared with placebo. Four patients in the rimonabant group and one in the placebo group committed suicide. Interpretation The premature termination of this trial has important lessons for drug development. A drug that was being marketed for weight loss, but being tested for improving cardiovascular outcomes, induced a level of serious neuropsychiatric effects that was deemed unacceptable by regulatory authorities, and both the drug and the trial were abruptly terminated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据